The Summit features an exciting line-up of leaders in the space as well as next generation players from Altimmune, Amgen, Corbus Pharmaceuticals and Eli Lilly, to FlyteHealth, Novo Nordisk ...

The Summit features an exciting line-up of leaders in the space as well as next generation players from Altimmune, Amgen, Corbus Pharmaceuticals and Eli Lilly, to FlyteHealth, Novo Nordisk, Roman ...

Another big pharma in the RNA business is Eli Lilly, which has been spending quite the penny ... biotech had inked an ADC deal with another Massachusetts-based biotech Corbus Pharmaceuticals. The ...

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a biopharmaceutical company currently valued at $71 million, announced on Thursday that Dr. Peter Salzmann has decided not to seek re-election ...

Corbus Pharmaceuticals (CRBP) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which ...

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a biopharmaceutical company with a market capitalization of $77 million, announced on Monday the appointment of Ian Hodgson as the new Chief ...

Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP – Get Free Report) have earned an average recommendation of “Buy” from the nine analysts that are currently covering the firm ...

Shares of CRBP stock opened at $6.79 on Wednesday. The stock’s 50-day simple moving average is $9.44 and its 200-day simple moving average is $18.99. The firm has a market capitalization of $82. ...

Fintel reports that on February 28, 2025, William Blair initiated coverage of Corbus Pharmaceuticals Holdings (NasdaqCM:CRBP) with a Outperform recommendation. Analyst Price Forecast Suggests 690. ...